Ibio Inc IBIO

Healthcare Biotechnology

iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. Its pre-clinical pipeline of immuno-oncology targets the treatment of solid tumors, glioblastoma, head, and neck cancers. Its pipeline includes IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.

NYSEAM:IBIO - Post by User

Ibio Inc

<< Previous

Bullboard Posts

Next >>

Post by FelixFunon Jul 30, 2020 9:52am

257 Views

Post# 31342775

CEO Tom Isett talks TODAY at 3:30 - $iBio

"Look forward to discussing what’s possible in massive plant-based #vaccine manufacturing and its two vaccine candidates with #iBio CEO Tom Isett on today’s #coronavirus report"

Company Overview
iBio, Inc. (NYSE MKT: IBIO), a leader in the plant-made pharmaceutical field, develops and offers pharmaceutical product applications using its iBio Technology platform.
The iBio Technology platform is a proprietary, transformative technology for the production of biologics including monoclonal antibodies, other therapeutic proteins and vaccines.

#iBio $iBio iBio

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario